GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » EV-to-EBIT

Syntara (ASX:SNT) EV-to-EBIT : -3.08 (As of Sep. 26, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Syntara EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Syntara's Enterprise Value is A$40.89 Mil. Syntara's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-13.28 Mil. Therefore, Syntara's EV-to-EBIT for today is -3.08.

The historical rank and industry rank for Syntara's EV-to-EBIT or its related term are showing as below:

ASX:SNT' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.94   Med: -1.42   Max: 12.3
Current: -3.08

During the past 13 years, the highest EV-to-EBIT of Syntara was 12.30. The lowest was -17.94. And the median was -1.42.

ASX:SNT's EV-to-EBIT is ranked worse than
100% of 667 companies
in the Drug Manufacturers industry
Industry Median: 16.23 vs ASX:SNT: -3.08

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Syntara's Enterprise Value for the quarter that ended in Dec. 2023 was A$11.38 Mil. Syntara's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-13.28 Mil. Syntara's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -116.70%.


Syntara EV-to-EBIT Historical Data

The historical data trend for Syntara's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara EV-to-EBIT Chart

Syntara Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.98 -10.73 -2.02 -2.52 -1.55

Syntara Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.02 - -2.52 - -

Competitive Comparison of Syntara's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Syntara's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syntara's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syntara's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Syntara's EV-to-EBIT falls into.



Syntara EV-to-EBIT Calculation

Syntara's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=40.892/-13.28
=-3.08

Syntara's current Enterprise Value is A$40.89 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Syntara's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-13.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syntara  (ASX:SNT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Syntara's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-13.28/11.37912
=-116.70 %

Syntara's Enterprise Value for the quarter that ended in Dec. 2023 was A$11.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Syntara's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-13.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syntara EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Syntara's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Syntara Business Description

Traded in Other Exchanges
Address
20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.